Mohammad AskarPublic working copy · medical review pending

Anterior uveitis · 143

Anterior uveitis: identify the pattern and control the cause

Cells, iris and corneal findings guide targeted assessment and follow-up.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Count and document activity, assess infection and systemic associations, then match anti-inflammatory and cause-directed treatment.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Describe activity and course first

Anterior uveitis has its primary inflammation in the anterior chamber; minor anterior vitreous spillover does not change that classification. Cells support active anterior inflammation. Flare reflects blood–aqueous barrier disturbance and can persist after cell activity subsides; it is not simply proof of an old episode or, alone, a universal activity measure. 1 2

SUN anterior cells are grade 0 below 1 cell, 0.5+ at 1–5, 1+ at 6–15, 2+ at 16–25, 3+ at 26–50 and 4+ above 50 cells in that field. Hypopyon is recorded separately, not automatically converted to cell grade 4+. Fibrin can obscure assessment and belongs in its own description; severe flare with fibrin is not the same scale as cell count. Vitreous haze is graded by disc and vessel visibility, separately from anterior cells. 2

Describe onset as sudden or insidious and duration as limited (up to 3 months) or persistent (more than 3 months). Acute means sudden onset with limited duration; recurrent episodes are separated by at least 3 months of inactivity without treatment. Chronic disease is persistent and relapses promptly, within 3 months after treatment stops. Duration alone is not the entire course classification. 2

Granulomatous morphology includes large mutton-fat KPs and iris nodules; fine KPs suggest non-granulomatous disease, without proving an aetiology. Immune-mediated, infectious and unexplained disease overlap clinically. The original infectious up-to20% and idiopathic up-to40% estimates lack a defined population here and must not be taught as universal prevalence. 1

Describe activity and course first
GradeCells in 1×1 mm field
0<1
0.5+1–5
1+6–15
2+16–25
3+26–50
4+>50

02Read the cornea, iris and pressure together

Pain, photophobia, ciliary redness and blur are common but not obligatory; JIA children may have asymptomatic white eyes. Ciliary injection is a clue rather than a reliable separation from every conjunctivitis or keratitis. Examine before dilation where feasible and assess the posterior segment as well. 1

Document fine, mutton-fat, pigmented or stellate KPs; old pigment deposits may persist, and a Krukenberg spindle is pigment rather than proof of uveitis. Band keratopathy reflects chronic inflammation or calcium disorders. Record cells/flare, hypopyon, hyphema, Koeppe nodules at the pupil, Busacca nodules on the stroma, posterior synechiae and diffuse/sectoral iris atrophy. None of these signs alone is pathognomonic. 1

Granulomatous disease raises sarcoid, TB and herpes questions. Hypopyon can accompany HLA-B27 or Behçet, but infection and malignancy remain alternatives; an irregular blood-stained pseudohypopyon can suggest leukaemia. The original Behçet10% estimate is population-dependent and unverified here. Hyphema or keratouveitis can suggest herpes, while sclerouveitis requires attention to infection and systemic vasculitis such as GPA (formerly Wegener) or PAN. 1

03Distinguish recurrent acute patterns

HLA-B27-associated spondyloarthritis often causes acute, recurrent, unilateral non-granulomatous disease that may alternate eyes. Fibrin, synechiae, hypopyon and CME may occur. The original example of 0.5+ rising to3–4+ over 1–2 days illustrates possible rapid escalation, not a mandatory prodrome or a reason to wait. IBD can present more insidiously or bilaterally. Ocular disease can precede joint/bowel symptoms; the original up-to10 years needs its source and should not define a fixed screening interval. 1

TINU often presents with bilateral anterior inflammation and renal abnormalities; it is not confined to adolescent girls. Fever, arthralgia, weight loss, creatinine, urinalysis and urinary beta-2-microglobulin can guide renal assessment; the original mean age 20 years is not a universal diagnostic benchmark. Coordinate nephrology when appropriate. 1

Unilateral hypertensive keratouveitis, reduced corneal sensation and sectoral iris atrophy suggest HSV/VZV, but CMV may overlap. Posner–Schlossman describes marked pressure elevation with mild cells, sometimes 0.5+, over hours/days; CMV is an important cause but not every case is viral-confirmed. Choose aqueous PCR when it will clarify management; absence of atrophy or sensory change is not by itself a universal mandate or exclusion test. 1 4

Consider mechanical UGH from iris chafing by an IOL, even occasionally an in-the-bag lens, rather than assuming every pseudophakic inflammation is autoimmune. Capsule rupture, trauma, hypermature lens or retained lens material can cause lens-related inflammation. Review medicines, including bisphosphonates and historical metipranolol; an association requires clinical assessment rather than automatic withdrawal of essential treatment. 1

04Recognise chronic disease without rigid exclusions

JIA-associated chronic anterior uveitis is often bilateral, non-granulomatous and silent in children under 16, but presentations vary. ANA positivity, young onset (original below 7 years) and oligoarticular disease (original fewer than 5 joints) inform risk; female sex is not a standalone marker of severe outcome. Band keratopathy, synechiae, glaucoma, cataract, CME, phthisis and amblyopia make screening essential. The selected ACR guideline conditionally recommends 3-month screening for high-risk children, not a universal 3–4 month schedule for every child. 3

Fuchs is often chronic, unilateral and mild with stellate KPs, diffuse stromal atrophy, possible heterochromia, vitritis and fine nodules/angle vessels. The original near 100% stellate-KP claim is not universal. Synechiae or preoperative CME should prompt reconsideration rather than act as infallible exclusions. Rubella-associated Fuchs and Fuchs-like CMV are not simply identical diseases; selected viral testing may alter treatment. Often manage cataract/glaucoma instead of prescribing indefinite steroids. 4 5

A selected antibody-positive cohort included 100 patients/107 eyes:86 rubella-positive and 21CMV-positive eyes. Only 9/86 rubella-positive eyes met all applied SUN Fuchs criteria. Selection, antibody rather than uniform PCR confirmation and classification-versus-diagnosis differences limit extrapolation; it illustrates phenotypic variability, not the prevalence or sensitivity of every clinical Fuchs sign. 5

Sarcoidosis may be bilateral granulomatous disease with KPs, nodules and synechiae. ACE/lysozyme and chest imaging support selected assessment; tissue can establish systemic disease, while ocular diagnostic categories can remain probable. TB may mimic it, but a positive PPD/IGRA or response to anti-TB treatment does not alone prove ocular TB. Coordinate infection assessment before immunosuppression. 1

Syphilis can imitate many patterns and needs appropriate paired serology. Consider brucellosis with relevant unpasteurised-dairy exposure, chronic postoperative endophthalmitis including Cutibacterium acnes (formerly P.acnes), and persistent viral disease. Months-to-years postoperative inflammation is not automatically sterile. Idiopathic disease is a conclusion after appropriate reassessment, not an exemption from infection review. Nummular keratitis can accompany the original brucellosis differential but does not establish it alone. 1

05Treat inflammation and cause with a monitored plan

Topical corticosteroids such as prednisolone acetate can control anterior inflammation, sometimes initially hourly, followed by an activity-guided taper. Product, severity, infection and pressure response matter; no fixed taper suits every patient. Viral disease may require organism-specific antiviral treatment with specialist-directed anti-inflammatory care rather than steroid monotherapy. 1 6

Cycloplegia reduces ciliary pain and helps prevent/break synechiae. Tropicamide or cyclopentolate and longer-acting atropine have different roles; the original blanket claim that atropine promotes adhesions is not a verified general rule. Severe, recurrent, bilateral or systemic disease may need methotrexate or selected biologics with rheumatology; anti-TNF and anti-IL-6 are not interchangeable universal first choices. 1 3 6

Monitor glaucoma/pressure and distinguish inflammation from steroid response. Elective cataract surgery often aims for at least 3 months of quiescence with a tailored perioperative plan, while childhood visual development or urgent pathology can change timing. A JIA label alone does not make every drainage implant preferable to trabeculectomy. Uveitic CME needs control of its cause; NSAIDs, local/systemic steroids or selected off-label anti-VEGF are not equally supported or interchangeable options. 1 3 6

Coordinate eye and systemic treatment even when joints appear quiet. Visits assess activity, pressure, lens, macula and drug toxicity; recurrence prevention and visual development matter alongside treating the present flare. ACR JIA monitoring is at least every 3 months when controlled on stable treatment and earlier after changes, including within 1 month of topical steroid changes and 2 months of systemic changes; this population-specific guidance does not define every adult schedule. 3

Treat inflammation and cause with a monitored plan
DiseaseTypical courseCluesAssociationManagement boundary
HLA-B27Acute recurrent unilateral/alternatingFibrin/hypopyon may occurSpondyloarthritis/IBDTreat activity; systemic care if needed
JIAChronic often bilateral silentWhite eye despite activityOligoarticular/ANA riskRisk-based screening; selected MTX/biologic
Viral anterior uveitisOften unilateral/keratouveitisPressure, sensation and iris patternHSV/VZV/CMV differSelected PCR and specific antiviral care
FuchsChronic mild often unilateralStellate KPs, atrophy, vitritisRubella/Fuchs-like CMV distinctionOften treat cataract/glaucoma; reassess atypical CME/synechiae
SarcoidosisOften bilateral granulomatousKPs, iris nodules, synechiaeSystemic sarcoidosisSelected imaging/tissue and steroid-sparing care
TBMay mimic sarcoidosisGranulomas/phlyctenules/test contextM.tuberculosisPositive test or response alone is not proof
TINUOften bilateral acuteRenal dysfunction/urinary beta-2-microglobulinNot limited to young womenCoordinate renal and ocular care
What are the main learning points?

Count and document activity, assess infection and systemic associations, then match anti-inflammatory and cause-directed treatment.

When is assessment urgent?

Rapid visual loss, severe pain, hypopyon, marked pressure rise, corneal ulcer or suspected infection/neurological disease needs urgent assessment; a quiet child’s eye still needs scheduled screening.

References and access status

  1. 1
    Immutable original export; anterior-uveitis lecture export; speaker/recording unverified

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    SUN first international workshop, 2005

    Historical SUN tables/definitions access 10 November from review 080 plus selected indexed statements 15 November; not new complete main-report access.

  3. 3
    ACR/AF JIA-associated uveitis guideline,2019

    Selected indexed Table 3 screening/monitoring recommendations read 15 November 2026; broader treatment scope from historical 080/081 ledgers. Not full guideline or high-certainty evidence for all paediatric uveitis.

  4. 4
    SUN CMV anterior uveitis criteria,2021

    Selected indexed original introduction/phenotype discussion read 15 November 2026; full machine-learning methods and performance tables not appraised.

  5. 5
    Rubella/CMV cohort and Fuchs classification,2022

    Complete indexed abstract and selected discussion read 15 November 2026; 100 patients 107 eyes, selected antibody-positive cohort; no complete methods/figures appraisal.

  6. 6
    Review 023/081: systemic therapy and infection source records

    Historical limited source appraisal reused; current full local product information, primary protocols and specialist case review pending.